MultICellTech.com is developing therapies for fatigue in MS patients, some cancer
About MultICellTech.com
MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms. MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats. MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics. MultiCell's pipeline of new drug candidates includes potential therapies for multiple sclerosis, the fatigue of MS, type-1 diabetes, certain cancers, as well as influenza and other health threats, based on patented drug development technology platforms. MultiCell has patented methods of modulating the human immune system to treat serious autoimmune diseases. MultiCell's majority owned subsidiary, Xenogenics has rights to the Ideal TM bioabsorbable stent.
